annotation_id large_string | subject large_string | rsid large_string | gene large_string | genotype large_string | evidence_level large_string | phenotype_category large_string | drugs large_string | phenotypes large_string | annotation_text large_string | url large_string |
|---|---|---|---|---|---|---|---|---|---|---|
981419550 | rs2819742 | rs2819742 | RYR2 | GG | 3 | Toxicity | cerivastatin | Rhabdomyolysis | Patients with the GG genotype may have an increased risk of cerivastatin-associated rhabdomyolysis as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity. | https://www.clinpgx.org/clinicalAnnotation/981419550 |
981420042 | rs121434568 | rs121434568 | EGFR | GG | 1A | Efficacy | gefitinib | Non-Small Cell Lung Carcinoma | Patients with advanced non-small-cell lung cancer and an activating somatic EGFR mutation, for example the GG genotype at rs121434568 (also known as L858R), may have an increased response to gefitinib, as measured by response rate and progression-free survival time, as compared to patients who do not have an activating... | https://www.clinpgx.org/clinicalAnnotation/981420042 |
981420042 | rs121434568 | rs121434568 | EGFR | GT | 1A | Efficacy | gefitinib | Non-Small Cell Lung Carcinoma | Patients with advanced non-small-cell lung cancer and an activating somatic EGFR mutation, for example the GT genotype at rs121434568 (also known as L858R), may have an increased response to gefitinib, as measured by response rate and progression-free survival time, as compared to patients who do not have an activating... | https://www.clinpgx.org/clinicalAnnotation/981420042 |
981420042 | rs121434568 | rs121434568 | EGFR | TT | 1A | Efficacy | gefitinib | Non-Small Cell Lung Carcinoma | Patients with advanced non-small-cell lung cancer and who do not carry an activating somatic EGFR mutation, for example the TT genotype at rs121434568 (also known as L858R), may have a decreased response to gefitinib, as measured by response rate and progression-free survival time, as compared to patients who have an a... | https://www.clinpgx.org/clinicalAnnotation/981420042 |
981475450 | rs121434569 | rs121434569 | EGFR | CC | 2B | Efficacy | erlotinib | Adenocarcinoma;Drug Resistance;Lung Neoplasms;Non-Small Cell Lung Carcinoma | Patients with the somatic rs121434569 CC genotype (i.e. lacking the somatic T790M mutation) in combination with an activating EGFR mutation (e.g. L858R or exon 19 deletion) may have decreased likelihood of acquired resistance to erlotinib as compared to patients with the CT or TT genotypes. Other genetic and clinical f... | https://www.clinpgx.org/clinicalAnnotation/981475450 |
981475450 | rs121434569 | rs121434569 | EGFR | CT | 2B | Efficacy | erlotinib | Adenocarcinoma;Drug Resistance;Lung Neoplasms;Non-Small Cell Lung Carcinoma | Patients with the somatic rs121434569 CT genotype (i.e. carrying one copy of the somatic T790M mutation) in combination with an activating EGFR mutation (e.g. L858R or exon 19 deletion) may have increased likelihood of acquired resistance to erlotinib compared to patients with CC genotype. Other genetic and clinical fa... | https://www.clinpgx.org/clinicalAnnotation/981475450 |
981475450 | rs121434569 | rs121434569 | EGFR | TT | 2B | Efficacy | erlotinib | Adenocarcinoma;Drug Resistance;Lung Neoplasms;Non-Small Cell Lung Carcinoma | Patients with the somatic rs121434569 TT genotype, (i.e. carrying two copies of the somatic T790M mutation) in combination with an activating EGFR mutation (e.g. L858R or exon 19 deletion) may have increased likelihood of acquired resistance to erlotinib as compared to patients with the CC genotype. Other genetic and c... | https://www.clinpgx.org/clinicalAnnotation/981475450 |
981475986 | rs11568315 | rs11568315 | EGFR | (CA)16/(CA)16 | 3 | Efficacy | gefitinib | Non-Small Cell Lung Carcinoma | Patients with the (CA)16/(CA)16 genotype and non-small cell lung cancer may have increased clinical response when treated with gefitinib as compared to patients with the (CA)17/(CA)17. Other genetic and clinical factors may also influence gefitinib response. | https://www.clinpgx.org/clinicalAnnotation/981475986 |
981475986 | rs11568315 | rs11568315 | EGFR | (CA)16/(CA)17 | 3 | Efficacy | gefitinib | Non-Small Cell Lung Carcinoma | Patients with the (CA)16/(CA)17 genotype and non-small cell lung cancer may have increased clinical response when treated with gefitinib as compared to patients with the (CA)17/(CA)17. Other genetic and clinical factors may also influence gefitinib response. | https://www.clinpgx.org/clinicalAnnotation/981475986 |
981475986 | rs11568315 | rs11568315 | EGFR | (CA)17/(CA)17 | 3 | Efficacy | gefitinib | Non-Small Cell Lung Carcinoma | Patients with the (CA)17/(CA)17 genotype and non-small cell lung cancer may have decreased clinical response when treated with gefitinib as compared to patients with the (CA)16/(CA)16 or (CA)16/(CA)17. Other genetic and clinical factors may also influence gefitinib response. | https://www.clinpgx.org/clinicalAnnotation/981475986 |
981478113 | rs10800397 | rs10800397 | NOS1AP | CC | 3 | Toxicity | amiodarone | Long QT Syndrome | Patients with the CC genotype may have decreased risk of drug-induced ventricular arrhythmia and QT prolongation when treated with amiodarone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced ventricular arrhythmia and QT prolongation. | https://www.clinpgx.org/clinicalAnnotation/981478113 |
981478113 | rs10800397 | rs10800397 | NOS1AP | CT | 3 | Toxicity | amiodarone | Long QT Syndrome | Patients with the CT genotype may have increased risk of drug-induced ventricular arrhythmia and QT prolongation when treated with amiodarone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced ventricular arrhythmia and QT prolongation. | https://www.clinpgx.org/clinicalAnnotation/981478113 |
981478113 | rs10800397 | rs10800397 | NOS1AP | TT | 3 | Toxicity | amiodarone | Long QT Syndrome | Patients with the TT genotype may have increased risk of drug-induced ventricular arrhythmia and QT prolongation when treated with amiodarone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced ventricular arrhythmia and QT prolongation. | https://www.clinpgx.org/clinicalAnnotation/981478113 |
981478131 | rs10919035 | rs10919035 | NOS1AP | CC | 3 | Toxicity | amiodarone | Long QT Syndrome | Patients with the CC genotype may have decreased risk of drug-induced ventricular arrhythmia and QT prolongation when treated with amiodarone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced ventricular arrhythmia and QT prolongation. | https://www.clinpgx.org/clinicalAnnotation/981478131 |
981478131 | rs10919035 | rs10919035 | NOS1AP | CT | 3 | Toxicity | amiodarone | Long QT Syndrome | Patients with the CT genotype may have increased risk of drug-induced ventricular arrhythmia and QT prolongation when treated with amiodarone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced ventricular arrhythmia and QT prolongation. | https://www.clinpgx.org/clinicalAnnotation/981478131 |
981478131 | rs10919035 | rs10919035 | NOS1AP | TT | 3 | Toxicity | amiodarone | Long QT Syndrome | Patients with the TT genotype may have increased risk of drug-induced ventricular arrhythmia and QT prolongation when treated with amiodarone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced ventricular arrhythmia and QT prolongation. | https://www.clinpgx.org/clinicalAnnotation/981478131 |
981755803 | rs75527207 | rs75527207 | CFTR | AA | 1A | Efficacy | ivacaftor | Cystic Fibrosis | Patients with the rs75527207 AA genotype (two copies of the CFTR G551D variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of G551D. Other genetic and clinical factors may... | https://www.clinpgx.org/clinicalAnnotation/981755803 |
981755803 | rs75527207 | rs75527207 | CFTR | AG | 1A | Efficacy | ivacaftor | Cystic Fibrosis | Patients with the rs75527207 AG genotype (one copy of the CFTR G551D variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of G551D. Other genetic and clinical factors may a... | https://www.clinpgx.org/clinicalAnnotation/981755803 |
981755803 | rs75527207 | rs75527207 | CFTR | GG | 1A | Efficacy | ivacaftor | Cystic Fibrosis | Patients with the rs75527207 GG genotype (do not have a copy of the CFTR G551D variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor. | https://www.clinpgx.org/clinicalAnnotation/981755803 |
981755820 | rs113993960 | rs113993960 | CFTR | CTT/CTT | 4 | Efficacy | ivacaftor | Cystic Fibrosis | The current evidence base suggests that there is no significant association between the rs113993960 CTT/CTT genotype (no copies of the CFTR F508del variant) and response to ivacaftor. However, conflicting evidence has been reported. Indication of ivacaftor in cystic fibrosis patients with this genotype is dependent on ... | https://www.clinpgx.org/clinicalAnnotation/981755820 |
981755820 | rs113993960 | rs113993960 | CFTR | CTT/del | 4 | Efficacy | ivacaftor | Cystic Fibrosis | The current evidence base suggests that there is no significant association between the rs113993960 CTT/del genotype (one copy of the CFTR F508del variant) and response to ivacaftor. However, conflicting evidence has been reported. Indication of ivacaftor in cystic fibrosis patients with this genotype is dependent on t... | https://www.clinpgx.org/clinicalAnnotation/981755820 |
981755820 | rs113993960 | rs113993960 | CFTR | del/del | 4 | Efficacy | ivacaftor | Cystic Fibrosis | The current evidence base suggests that there is no significant association between the rs113993960 del/del genotype (two copies of the CFTR F508del variant) and response to ivacaftor. However, conflicting evidence has been reported. Ivacaftor is not recommended in cystic fibrosis patients with this genotype. FDA-appro... | https://www.clinpgx.org/clinicalAnnotation/981755820 |
982009415 | rs1137617 | rs1137617 | KCNH2 | AA | 3 | Efficacy | Calcium channel blockers;nitrendipine | Essential hypertension | Patients with the AA genotype with essential hypertension who are treated with calcium channel blockers may have greater reductions in diastolic blood pressure and mean arterial pressure as compared to patients with the GG genotype. Male patients with the AA genotype may also have greater reductions in systolic blood p... | https://www.clinpgx.org/clinicalAnnotation/982009415 |
982009415 | rs1137617 | rs1137617 | KCNH2 | AG | 3 | Efficacy | Calcium channel blockers;nitrendipine | Essential hypertension | Patients with the AG genotype with essential hypertension who are treated with calcium channel blockers may have greater reductions in diastolic blood pressure and mean arterial pressure as compared to patients with the GG genotype. Male patients with the AG genotype may also have greater reductions in systolic blood p... | https://www.clinpgx.org/clinicalAnnotation/982009415 |
982009415 | rs1137617 | rs1137617 | KCNH2 | GG | 3 | Efficacy | Calcium channel blockers;nitrendipine | Essential hypertension | Patients with the GG genotype with essential hypertension who are treated with calcium channel blockers may have smaller reductions in diastolic blood pressure and mean arterial pressure as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to ant... | https://www.clinpgx.org/clinicalAnnotation/982009415 |
982014094 | CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*35xN | null | CYP2D6 | *1 | 1A | Efficacy | ondansetron | Vomiting | The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have a similar response to ondansetron as compared to patients with two decreased or no function alleles or a no function allele in combinati... | https://www.clinpgx.org/clinicalAnnotation/982014094 |
982014094 | CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*35xN | null | CYP2D6 | *10 | 1A | Efficacy | ondansetron | Vomiting | The CYP2C6*10 allele has been assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the *10 allele in combination with a decreased or no function allele or an increased function allele with an activity value of 2 may have a similar response to ondansetron as compared to patie... | https://www.clinpgx.org/clinicalAnnotation/982014094 |
982014094 | CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*35xN | null | CYP2D6 | *1xN | 1A | Efficacy | ondansetron | Vomiting | The CYP2D6*1xN alleles (*1x2 and *1x≥3) are assigned as increased function alleles by CPIC. Patients carrying a *1xN allele in combination with an increased or normal function allele or a decreased function allele with an activity value of 0.5 may have a decreased response to ondansetron as compared to patients with al... | https://www.clinpgx.org/clinicalAnnotation/982014094 |
982014094 | CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*35xN | null | CYP2D6 | *2 | 1A | Efficacy | ondansetron | Vomiting | The CYP2D6*2 allele is assigned as a normal function allele by CPIC. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may have a similar response to ondansetron as compared to patients with two decreased or no function alleles or a no function allele in combinati... | https://www.clinpgx.org/clinicalAnnotation/982014094 |
982014094 | CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*35xN | null | CYP2D6 | *2xN | 1A | Efficacy | ondansetron | Vomiting | The CYP2D6*2xN alleles (*2x2 and *2x≥3) are assigned as increased function alleles by CPIC. Patients carrying a *2xN allele in combination with an increased or normal function allele or a decreased function allele with an activity value of 0.5 may have a decreased response to ondansetron as compared to patients with al... | https://www.clinpgx.org/clinicalAnnotation/982014094 |
982014094 | CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*35xN | null | CYP2D6 | *35xN | 1A | Efficacy | ondansetron | Vomiting | The CYP2D6*35xN alleles (*35x2) is assigned as an increased function allele by CPIC. Patients carrying a *35xN allele in combination with an increased or normal function allele or a decreased function allele with an activity value of 0.5 may have a decreased response to ondansetron as compared to patients with alleles ... | https://www.clinpgx.org/clinicalAnnotation/982014094 |
982014094 | CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*35xN | null | CYP2D6 | *4 | 1A | Efficacy | ondansetron | Vomiting | The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with decreased, normal or no function allele or an increased function allele with an activity value of 2 may have a similar response to ondansetron as compared to patients with alleles that result in a normal... | https://www.clinpgx.org/clinicalAnnotation/982014094 |
982014094 | CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*35xN | null | CYP2D6 | *5 | 1A | Efficacy | ondansetron | Vomiting | The CYP2D6*5 allele has been assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with a decreased, normal or no function allele or an increased function allele with an activity value of 2 may have a similar response to ondansetron as compared to patients with alleles that result in ... | https://www.clinpgx.org/clinicalAnnotation/982014094 |
982029200 | rs11572080 | rs11572080 | CYP2C8 | CC | 3 | Dosage | repaglinide | null | Patients with the CC genotype may have increased plasma concentrations of repaglinide in healthy volunteers as compared to patients with the TT or CT genotype. Other genetic or clinical factors may influence a patient's response to repaglinide. This variant was analyzed together with rs10509681 as part of CYP2C8*3 hapl... | https://www.clinpgx.org/clinicalAnnotation/982029200 |
982029200 | rs11572080 | rs11572080 | CYP2C8 | CT | 3 | Dosage | repaglinide | null | Patients with the CT genotype may have reduced plasma concentrations of repaglinide in healthy volunteers as compared to patients with the CC genotype. Other genetic or clinical factors may influence a patient's response to repaglinide. This variant was analyzed together with rs10509681 as part of CYP2C8*3 haplotype. | https://www.clinpgx.org/clinicalAnnotation/982029200 |
982029200 | rs11572080 | rs11572080 | CYP2C8 | TT | 3 | Dosage | repaglinide | null | Patients with the TT genotype may have reduced plasma concentrations of repaglinide in healthy volunteers as compared to patients with the CC genotype. Other genetic or clinical factors may influence a patient's response to repaglinide. This variant was analyzed together with rs10509681 as part of CYP2C8*3 haplotype. | https://www.clinpgx.org/clinicalAnnotation/982029200 |
982029578 | rs699947 | rs699947 | VEGFA | AA | 4 | Efficacy | ranibizumab | Macular Degeneration | Patients with the AA genotype and Macular Degeneration who are treated with ranibizumab may have a lack of early response to treatment compared to patients with the AC or CC genotype. No association with response was found in other studies. Other genetic and clinical factors may also influence a patient's response to r... | https://www.clinpgx.org/clinicalAnnotation/982029578 |
982029578 | rs699947 | rs699947 | VEGFA | AC | 4 | Efficacy | ranibizumab | Macular Degeneration | Patients with the AC genotype and Macular Degeneration who are treated with ranibizumab may have an early response to treatment compared to patients with the AA genotype. No association with response was found in other studies. Other genetic and clinical factors may also influence a patient's response to ranibizumab tr... | https://www.clinpgx.org/clinicalAnnotation/982029578 |
982029578 | rs699947 | rs699947 | VEGFA | CC | 4 | Efficacy | ranibizumab | Macular Degeneration | Patients with the CC genotype and Macular Degeneration who are treated with ranibizumab may have an early response to treatment compared to patients with the AA genotype. No association with response was found in other studies. Other genetic and clinical factors may also influence a patient's response to ranibizumab tr... | https://www.clinpgx.org/clinicalAnnotation/982029578 |
982029652 | rs324420 | rs324420 | FAAH | AA | 3 | Other | methamphetamine | Substance-Related Disorders | Patients with the AA genotype may have an increased risk for dependence on methamphetamine as compared to men with the CC genotype. Genotype was not associated with risk of methamphetamine-induced pyschosis or panic disorder. Other genetic and clinical factors may also influence dependence on methamphetamine and metham... | https://www.clinpgx.org/clinicalAnnotation/982029652 |
982029652 | rs324420 | rs324420 | FAAH | AC | 3 | Other | methamphetamine | Substance-Related Disorders | Patients with the AC genotype may have an increased risk for dependence on methamphetamine as compared to men with the CC genotype, or a decreased risk for dependence on methamphetamine as compared to men with the AA genotype. Genotype was not associated with risk of methamphetamine-induced pyschosis or panic disorder.... | https://www.clinpgx.org/clinicalAnnotation/982029652 |
982029652 | rs324420 | rs324420 | FAAH | CC | 3 | Other | methamphetamine | Substance-Related Disorders | Patients with the CC genotype may have a decreased risk for dependence on methamphetamine as compared to men with the AA genotype. Genotype was not associated with risk of methamphetamine-induced pyschosis or panic disorder. Other genetic and clinical factors may also influence dependence on methamphetamine and methamp... | https://www.clinpgx.org/clinicalAnnotation/982029652 |
982029857 | CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*35, CYP2D6*41 | null | CYP2D6 | *1 | 1A | Metabolism/PK | tamoxifen | Breast Neoplasms | The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype may have increased metabolism of tamoxifen resulting in increased endoxifen concentrations as compared to patients with a no function allel... | https://www.clinpgx.org/clinicalAnnotation/982029857 |
982029857 | CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*35, CYP2D6*41 | null | CYP2D6 | *10 | 1A | Metabolism/PK | tamoxifen | Breast Neoplasms | The CYP2D6*10 allele is assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the CYP2D6*10 allele in combination with a no, decreased function allele may have decreased metabolism of tamoxifen resulting in decreased endoxifen concentrations as compared to patients with allel... | https://www.clinpgx.org/clinicalAnnotation/982029857 |
982029857 | CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*35, CYP2D6*41 | null | CYP2D6 | *17 | 1A | Metabolism/PK | tamoxifen | Breast Neoplasms | The CYP2D6*17 allele is assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients carrying the CYP2D6*17 allele in combination with a no, decreased function allele may have decreased metabolism of tamoxifen resulting in decreased endoxifen concentrations as compared to patients with allele... | https://www.clinpgx.org/clinicalAnnotation/982029857 |
982029857 | CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*35, CYP2D6*41 | null | CYP2D6 | *2 | 1A | Metabolism/PK | tamoxifen | Breast Neoplasms | The CYP2D6*2 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2D6*2 allele in combination with alleles that result in a normal metabolizer phenotype may have increased metabolism of tamoxifen resulting in increased endoxifen concentrations as compared to patients with a no function allel... | https://www.clinpgx.org/clinicalAnnotation/982029857 |
982029857 | CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*35, CYP2D6*41 | null | CYP2D6 | *29 | 1A | Metabolism/PK | tamoxifen | Breast Neoplasms | The CYP2D6*29 allele is assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients carrying the CYP2D6*29 allele in combination with a no, decreased function allele may have decreased metabolism of tamoxifen resulting in decreased endoxifen concentrations as compared to patients with allele... | https://www.clinpgx.org/clinicalAnnotation/982029857 |
982029857 | CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*35, CYP2D6*41 | null | CYP2D6 | *3 | 1A | Metabolism/PK | tamoxifen | Breast Neoplasms | The CYP2D6*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*3 allele in combination with a no, decreased or normal function allele may have decreased metabolism of tamoxifen resulting in decreased endoxifen concentrations as compared to patients with alleles that result in a normal met... | https://www.clinpgx.org/clinicalAnnotation/982029857 |
982029857 | CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*35, CYP2D6*41 | null | CYP2D6 | *35 | 1A | Metabolism/PK | tamoxifen | Breast Neoplasms | The CYP2D6*35 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2D6*35 allele in combination with alleles that result in a normal metabolizer phenotype may have increased metabolism of tamoxifen resulting in increased endoxifen concentrations as compared to patients with a no function all... | https://www.clinpgx.org/clinicalAnnotation/982029857 |
982029857 | CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*35, CYP2D6*41 | null | CYP2D6 | *4 | 1A | Metabolism/PK | tamoxifen | Breast Neoplasms | The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*4 allele in combination with a no, decreased or normal function allele may have decreased metabolism of tamoxifen resulting in decreased endoxifen concentrations as compared to patients with alleles that result in a normal met... | https://www.clinpgx.org/clinicalAnnotation/982029857 |
982029857 | CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*35, CYP2D6*41 | null | CYP2D6 | *41 | 1A | Metabolism/PK | tamoxifen | Breast Neoplasms | The CYP2D6*41 allele is assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients carrying the CYP2D6*41 allele in combination with a no, decreased function allele may have decreased metabolism of tamoxifen resulting in decreased endoxifen concentrations as compared to patients with allele... | https://www.clinpgx.org/clinicalAnnotation/982029857 |
982029857 | CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*35, CYP2D6*41 | null | CYP2D6 | *5 | 1A | Metabolism/PK | tamoxifen | Breast Neoplasms | The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*5 allele in combination with a no, decreased or normal function allele may have decreased metabolism of tamoxifen resulting in decreased endoxifen concentrations as compared to patients with alleles that result in a normal met... | https://www.clinpgx.org/clinicalAnnotation/982029857 |
982029857 | CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*35, CYP2D6*41 | null | CYP2D6 | *6 | 1A | Metabolism/PK | tamoxifen | Breast Neoplasms | The CYP2D6*6 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*6 allele in combination with a no, decreased or normal function allele may have decreased metabolism of tamoxifen resulting in decreased endoxifen concentrations as compared to patients with alleles that result in a normal met... | https://www.clinpgx.org/clinicalAnnotation/982029857 |
982030222 | NAT2*1, NAT2*4, NAT2*5, NAT2*6, NAT2*6J, NAT2*7, NAT2*7G, NAT2*14, NAT2*16, NAT2*39 | null | NAT2 | *1 | 2A | Metabolism/PK | isoniazid | Tuberculosis | Patients with two copies of the NAT2*1 allele (formerly *12A, B, C) or one copy of the *1 allele in combination with one copy of *4 allele (*13A now also mapped under *4) may have increased metabolism of isoniazid as compared to patients with any of the following genotype combinations: one copy of the *1 or *4 allele i... | https://www.clinpgx.org/clinicalAnnotation/982030222 |
982030222 | NAT2*1, NAT2*4, NAT2*5, NAT2*6, NAT2*6J, NAT2*7, NAT2*7G, NAT2*14, NAT2*16, NAT2*39 | null | NAT2 | *14 | 2A | Metabolism/PK | isoniazid | Tuberculosis | Patients with two copies of the NAT2*14 allele or one copy of the *14 allele in combination with one copy of the *5, *6, *7, *14, *16 or *39 allele may have decreased metabolism of isoniazid as compared to patients with the *1 or *4 allele. Other genetic and clinical factors may also affect isoniazid metabolism. This a... | https://www.clinpgx.org/clinicalAnnotation/982030222 |
982030222 | NAT2*1, NAT2*4, NAT2*5, NAT2*6, NAT2*6J, NAT2*7, NAT2*7G, NAT2*14, NAT2*16, NAT2*39 | null | NAT2 | *16 | 2A | Metabolism/PK | isoniazid | Tuberculosis | Patients with two copies of the NAT2*16 allele (formerly *5A, *5D) or one copy of the *16 allele in combination with one copy of the *5, *6, *7, *14, *16 or *39 allele may have decreased metabolism of isoniazid as compared to patients with the *1 or *4 allele. Other genetic and clinical factors may also affect isoniazi... | https://www.clinpgx.org/clinicalAnnotation/982030222 |
982030222 | NAT2*1, NAT2*4, NAT2*5, NAT2*6, NAT2*6J, NAT2*7, NAT2*7G, NAT2*14, NAT2*16, NAT2*39 | null | NAT2 | *39 | 2A | Metabolism/PK | isoniazid | Tuberculosis | Patients with two copies of the NAT2*39 allele (formerly *6O) or one copy of the *14 allele in combination with one copy of the *5, *6, *7, *14, *16 or *39 allele may have decreased metabolism of isoniazid as compared to patients with the *1 or *4 allele. Other genetic and clinical factors may also affect isoniazid met... | https://www.clinpgx.org/clinicalAnnotation/982030222 |
982030222 | NAT2*1, NAT2*4, NAT2*5, NAT2*6, NAT2*6J, NAT2*7, NAT2*7G, NAT2*14, NAT2*16, NAT2*39 | null | NAT2 | *4 | 2A | Metabolism/PK | isoniazid | Tuberculosis | Patients with two copies of the NAT2*4 allele (*13A now also mapped under *4) or one copy of the *4 allele in combination with one copy of any *1 allele (formerly *12A, B, C) may have increased metabolism of isoniazid as compared to patients with any of the following genotype combinations: one copy of the *1 or *4 alle... | https://www.clinpgx.org/clinicalAnnotation/982030222 |
982030222 | NAT2*1, NAT2*4, NAT2*5, NAT2*6, NAT2*6J, NAT2*7, NAT2*7G, NAT2*14, NAT2*16, NAT2*39 | null | NAT2 | *5 | 2A | Metabolism/PK | isoniazid | Tuberculosis | Patients with two copies of the NAT2*5 allele or one copy of the *5 allele in combination with one copy of the *5, *6, *7, *14, *16 or *39 allele may have decreased metabolism of isoniazid as compared to patients with the *1 or *4 allele. Other genetic and clinical factors may also affect isoniazid metabolism. This ann... | https://www.clinpgx.org/clinicalAnnotation/982030222 |
982030222 | NAT2*1, NAT2*4, NAT2*5, NAT2*6, NAT2*6J, NAT2*7, NAT2*7G, NAT2*14, NAT2*16, NAT2*39 | null | NAT2 | *6 | 2A | Metabolism/PK | isoniazid | Tuberculosis | Patients with two copies of the NAT2*6 allele or one copy of the *6 allele in combination with one copy of the *5, *6, *7, *14, *16 or *39 allele may have decreased metabolism of isoniazid as compared to patients with the *1 or *4 allele. Other genetic and clinical factors may also affect isoniazid metabolism. This ann... | https://www.clinpgx.org/clinicalAnnotation/982030222 |
982030222 | NAT2*1, NAT2*4, NAT2*5, NAT2*6, NAT2*6J, NAT2*7, NAT2*7G, NAT2*14, NAT2*16, NAT2*39 | null | NAT2 | *6J | 2A | Metabolism/PK | isoniazid | Tuberculosis | Patients with two copies of the NAT2*6J allele or one copy of the *6J allele in combination with one copy of the *5, *6, *7, *14, *16 or *39 allele may have decreased metabolism of isoniazid as compared to patients with the *1 or *4 allele. Other genetic and clinical factors may also affect isoniazid metabolism. This a... | https://www.clinpgx.org/clinicalAnnotation/982030222 |
982030222 | NAT2*1, NAT2*4, NAT2*5, NAT2*6, NAT2*6J, NAT2*7, NAT2*7G, NAT2*14, NAT2*16, NAT2*39 | null | NAT2 | *7 | 2A | Metabolism/PK | isoniazid | Tuberculosis | Patients with two copies of the NAT2*7 allele or one copy of the *7 allele in combination with one copy of the *5, *6, *7, *14, *16 or *39 allele may have decreased metabolism of isoniazid as compared to patients with the *1 or *4 allele. Other genetic and clinical factors may also affect isoniazid metabolism. This ann... | https://www.clinpgx.org/clinicalAnnotation/982030222 |
982030222 | NAT2*1, NAT2*4, NAT2*5, NAT2*6, NAT2*6J, NAT2*7, NAT2*7G, NAT2*14, NAT2*16, NAT2*39 | null | NAT2 | *7G | 2A | Metabolism/PK | isoniazid | Tuberculosis | Patients with two copies of the NAT2*7G allele or one copy of the *7G allele in combination with one of the *5, *6, *7, *14, *16 or *39 may have decreased metabolism of isoniazid as compared to patients with the *1 or *4 allele. Other genetic and clinical factors may also affect isoniazid metabolism. This annotation on... | https://www.clinpgx.org/clinicalAnnotation/982030222 |
982030283 | GSTT1 non-null, GSTT1 null | null | GSTT1 | non-null/ non-null | 4 | Toxicity | Drugs For Treatment Of Tuberculosis;ethambutol;isoniazid;pyrazinamide;rifampin;streptomycin | Tuberculosis | Patients with the non-null/ non-null genotype (has two copies of the GSTT1 gene) and Tuberculosis may have a decreased risk of drug-induced hepatotoxicity when treated with an isoniazid-containing anti-TB drug regimen as compared to patients with the null/ null genotype. However, this association is not seen in the maj... | https://www.clinpgx.org/clinicalAnnotation/982030283 |
982030283 | GSTT1 non-null, GSTT1 null | null | GSTT1 | non-null/ null | 4 | Toxicity | Drugs For Treatment Of Tuberculosis;ethambutol;isoniazid;pyrazinamide;rifampin;streptomycin | Tuberculosis | Patients with the non-null/ null genotype (has one copy of the GSTT1 gene) and Tuberculosis may have a decreased risk of drug-induced hepatotoxicity when treated with an isoniazid-containing anti-TB drug regimen as compared to patients with the null/ null genotype. However, this association is not seen in the majority ... | https://www.clinpgx.org/clinicalAnnotation/982030283 |
982030283 | GSTT1 non-null, GSTT1 null | null | GSTT1 | null/null | 4 | Toxicity | Drugs For Treatment Of Tuberculosis;ethambutol;isoniazid;pyrazinamide;rifampin;streptomycin | Tuberculosis | Patients with the null/null (has no copies of the GSTT1 gene) genotype and Tuberculosis may have an increased risk of drug-induced hepatotoxicity when treated with an isoniazid-containing anti-TB drug regimen as compared to patients with the non-null/ null or the non-null/ non-null genotype. However, this association i... | https://www.clinpgx.org/clinicalAnnotation/982030283 |
982030308 | GSTM1 non-null, GSTM1 null | null | GSTM1 | non-null/ non-null | 4 | Toxicity | Drugs For Treatment Of Tuberculosis;ethambutol;isoniazid;pyrazinamide;rifampin;streptomycin | Tuberculosis | Patients with the non-null/ non-null genotype (has two copies of the GSTM1 gene) and Tuberculosis may have a decreased risk of drug-induced hepatotoxicity when treated with an isoniazid-containing anti-TB drug regimen as compared to patients with the null/ null genotype. However, this association is not seen in the maj... | https://www.clinpgx.org/clinicalAnnotation/982030308 |
982030308 | GSTM1 non-null, GSTM1 null | null | GSTM1 | non-null/ null | 4 | Toxicity | Drugs For Treatment Of Tuberculosis;ethambutol;isoniazid;pyrazinamide;rifampin;streptomycin | Tuberculosis | Patients with the non-null/ null genotype (has one copy of the GSTM1 gene) and Tuberculosis may have a decreased risk of drug-induced hepatotoxicity when treated with an isoniazid-containing anti-TB drug regimen as compared to patients with the null/ null genotype. However, this association is not seen in the majority ... | https://www.clinpgx.org/clinicalAnnotation/982030308 |
982030308 | GSTM1 non-null, GSTM1 null | null | GSTM1 | null/null | 4 | Toxicity | Drugs For Treatment Of Tuberculosis;ethambutol;isoniazid;pyrazinamide;rifampin;streptomycin | Tuberculosis | Patients with the null/null (has no copies of the GSTM1 gene) genotype and Tuberculosis may have an increased risk of drug-induced hepatotoxicity when treated with an isoniazid-containing anti-TB drug regimen as compared to patients with the non-null/ null or the non-null/ non-null genotype. However, this association i... | https://www.clinpgx.org/clinicalAnnotation/982030308 |
982030369 | rs12777823 | rs12777823 | null | AA | 1A | Dosage | warfarin | null | Patients with the rs12777823 AA genotype may require a lower dose of warfarin in African Americans as compared to patients with the GG genotype. Other genetic and clinical factors may also influence warfarin dosage. | https://www.clinpgx.org/clinicalAnnotation/982030369 |
982030369 | rs12777823 | rs12777823 | null | AG | 1A | Dosage | warfarin | null | Patients with the rs12777823 AG genotype may require a lower dose of warfarin in African Americans as compared to patients with the GG genotype. Other genetic and clinical factors may also influence warfarin dosage. | https://www.clinpgx.org/clinicalAnnotation/982030369 |
982030369 | rs12777823 | rs12777823 | null | GG | 1A | Dosage | warfarin | null | Patients with the rs12777823 GG genotype may require a higher dose of warfarin in African Americans as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence warfarin dosage. | https://www.clinpgx.org/clinicalAnnotation/982030369 |
982030381 | rs1954787 | rs1954787 | GRIK4 | CC | 3 | Efficacy | antidepressants | Depressive Disorder | Patients with the rs1954787 CC genotype and depressive disorders may be more likely to respond to antidepressant treatment as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to antidepressants. | https://www.clinpgx.org/clinicalAnnotation/982030381 |
982030381 | rs1954787 | rs1954787 | GRIK4 | CT | 3 | Efficacy | antidepressants | Depressive Disorder | Patients with the rs1954787 CT genotype and depressive disorders may be less likely to respond to antidepressant treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antidepressants. | https://www.clinpgx.org/clinicalAnnotation/982030381 |
982030381 | rs1954787 | rs1954787 | GRIK4 | TT | 3 | Efficacy | antidepressants | Depressive Disorder | Patients with the rs1954787 TT genotype and depressive disorders may be less likely to respond to antidepressant treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antidepressants. | https://www.clinpgx.org/clinicalAnnotation/982030381 |
982030399 | rs3810651 | rs3810651 | GABRQ | AA | 3 | Efficacy | venlafaxine | Major Depressive Disorder | Patients with the AA genotype and Major Depressive Disorder may be more likely to respond to venlafaxine treatment as compared to those with the TT genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine treatment. | https://www.clinpgx.org/clinicalAnnotation/982030399 |
982030399 | rs3810651 | rs3810651 | GABRQ | AT | 3 | Efficacy | venlafaxine | Major Depressive Disorder | Patients with the AT genotype and Major Depressive Disorder may be more likely to respond to venlafaxine treatment as compared to those with the TT genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine treatment. | https://www.clinpgx.org/clinicalAnnotation/982030399 |
982030399 | rs3810651 | rs3810651 | GABRQ | TT | 3 | Efficacy | venlafaxine | Major Depressive Disorder | Patients with the TT genotype and Major Depressive Disorder may be less likely to respond to venlafaxine treatment as compared to those with the AA or AT genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine treatment. | https://www.clinpgx.org/clinicalAnnotation/982030399 |
982030732 | rs762551 | rs762551 | CYP1A2 | AA | 3 | Efficacy | clopidogrel | null | Patients with the AA genotype may have decreased on-treatment platelet reactivity when treated with clopidogrel as compared to patients with the CC genotype. However, another study found no association with risk of major adverse cardiac events. Other genetic and clinical factors may influence a patient's response to cl... | https://www.clinpgx.org/clinicalAnnotation/982030732 |
982030732 | rs762551 | rs762551 | CYP1A2 | AC | 3 | Efficacy | clopidogrel | null | Patients with the AC genotype may have decreased on-treatment platelet reactivity when treated with clopidogrel as compared to patients with the CC genotype. However, another study found no association with risk of major adverse cardiac events. Other genetic and clinical factors may influence a patient's response to cl... | https://www.clinpgx.org/clinicalAnnotation/982030732 |
982030732 | rs762551 | rs762551 | CYP1A2 | CC | 3 | Efficacy | clopidogrel | null | Patients with the CC genotype may have increased on-treatment platelet reactivity when treated with clopidogrel as compared to patients with the AC + CC genotype. However, another study found no association with risk of major adverse cardiac events. Other genetic and clinical factors may influence a patient's response ... | https://www.clinpgx.org/clinicalAnnotation/982030732 |
982030757 | rs2297480 | rs2297480 | FDPS | GG | 3 | Toxicity | zoledronate | Neoplasms;Osteonecrosis | Patients with genotype GG may have decreased likelihood of osteonecrosis when treated with zoledronate in people with Neoplasms as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's chance of response. | https://www.clinpgx.org/clinicalAnnotation/982030757 |
982030757 | rs2297480 | rs2297480 | FDPS | TG | 3 | Toxicity | zoledronate | Neoplasms;Osteonecrosis | Patients with genotype TG may have increased likelihood of osteonecrosis when treated with zoledronate in people with Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's chance of response. | https://www.clinpgx.org/clinicalAnnotation/982030757 |
982030757 | rs2297480 | rs2297480 | FDPS | TT | 3 | Toxicity | zoledronate | Neoplasms;Osteonecrosis | Patients with genotype TT may have increased likelihood of osteonecrosis when treated with zoledronate in people with Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's chance of response. | https://www.clinpgx.org/clinicalAnnotation/982030757 |
982030805 | rs71647871 | rs71647871 | CES1 | CC | 2B | Metabolism/PK | clopidogrel | null | Patients with the rs71647871 CC genotype who are treated with clopidogrel may have decreased exposure to clopidogrel as compared to patients with the CT or TT genotype. This annotation only covers the pharmacokinetic relationship between rs71647871 and clopidogrel and does not include evidence about clinical outcomes. ... | https://www.clinpgx.org/clinicalAnnotation/982030805 |
982030805 | rs71647871 | rs71647871 | CES1 | CT | 2B | Metabolism/PK | clopidogrel | null | Patients with the rs71647871 CT genotype who are treated with clopidogrel may have increased exposure to clopidogrel as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs71647871 and clopidogrel and does not include evidence about clinical outcomes. Other ... | https://www.clinpgx.org/clinicalAnnotation/982030805 |
982030805 | rs71647871 | rs71647871 | CES1 | TT | 2B | Metabolism/PK | clopidogrel | null | Patients with the rs71647871 TT genotype who are treated with clopidogrel may have increased exposure to clopidogrel as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs71647871 and clopidogrel and does not include evidence about clinical outcomes. Other ... | https://www.clinpgx.org/clinicalAnnotation/982030805 |
982030836 | rs10929302 | rs10929302 | UGT1A1 | AA | 2A | Toxicity | irinotecan | Neutropenia | Patients with the rs10929302 AA genotype may have increased risk of neutropenia when treated with irinotecan as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence irinotecan-related toxicity. | https://www.clinpgx.org/clinicalAnnotation/982030836 |
982030836 | rs10929302 | rs10929302 | UGT1A1 | AG | 2A | Toxicity | irinotecan | Neutropenia | Patients with the rs10929302 AG genotype may have decreased risk of neutropenia when treated with irinotecan as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence irinotecan-related toxicity. | https://www.clinpgx.org/clinicalAnnotation/982030836 |
982030836 | rs10929302 | rs10929302 | UGT1A1 | GG | 2A | Toxicity | irinotecan | Neutropenia | Patients with the rs10929302 GG genotype may have decreased risk of neutropenia when treated with irinotecan as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence irinotecan-related toxicity. | https://www.clinpgx.org/clinicalAnnotation/982030836 |
982030854 | rs9606186 | rs9606186 | COMT | CC | 3 | Efficacy | risperidone | Schizophrenia | Patients with the rs9606186 CC genotype and Schizophrenia may be less likely to respond when treated with risperidone as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may influence response to risperidone. | https://www.clinpgx.org/clinicalAnnotation/982030854 |
982030854 | rs9606186 | rs9606186 | COMT | CG | 3 | Efficacy | risperidone | Schizophrenia | Patients with the rs9606186 CG genotype and Schizophrenia may be less likely to respond when treated with risperidone as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may influence response to risperidone. | https://www.clinpgx.org/clinicalAnnotation/982030854 |
982030854 | rs9606186 | rs9606186 | COMT | GG | 3 | Efficacy | risperidone | Schizophrenia | Patients with the rs9606186 GG genotype and Schizophrenia may be more likely to respond when treated with risperidone as compared to patients with the CG or CC genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may influence response to risperidone. | https://www.clinpgx.org/clinicalAnnotation/982030854 |
982030862 | rs1992647 | rs1992647 | GABRA6 | AA | 3 | Efficacy | antidepressants;Selective serotonin reuptake inhibitors;venlafaxine | Major Depressive Disorder | Patients with the AA genotype and Major Depressive Disorder may be less likely to respond to antidepressant treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment. | https://www.clinpgx.org/clinicalAnnotation/982030862 |
982030862 | rs1992647 | rs1992647 | GABRA6 | AG | 3 | Efficacy | antidepressants;Selective serotonin reuptake inhibitors;venlafaxine | Major Depressive Disorder | Patients with the AG genotype and Major Depressive Disorder may be more likely to respond to anti-depressant treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment. | https://www.clinpgx.org/clinicalAnnotation/982030862 |
982030862 | rs1992647 | rs1992647 | GABRA6 | GG | 3 | Efficacy | antidepressants;Selective serotonin reuptake inhibitors;venlafaxine | Major Depressive Disorder | Patients with the GG genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment. | https://www.clinpgx.org/clinicalAnnotation/982030862 |
982030873 | rs10036156 | rs10036156 | GABRP | CC | 3 | Efficacy | antidepressants;Selective serotonin reuptake inhibitors;venlafaxine | Major Depressive Disorder | Patients with the CC genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment. | https://www.clinpgx.org/clinicalAnnotation/982030873 |
982030873 | rs10036156 | rs10036156 | GABRP | CT | 3 | Efficacy | antidepressants;Selective serotonin reuptake inhibitors;venlafaxine | Major Depressive Disorder | Patients with the CT genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment. | https://www.clinpgx.org/clinicalAnnotation/982030873 |
982030873 | rs10036156 | rs10036156 | GABRP | TT | 3 | Efficacy | antidepressants;Selective serotonin reuptake inhibitors;venlafaxine | Major Depressive Disorder | Patients with the TT genotype and Major Depressive Disorder may be less likely to respond to antidepressant treatment as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment. | https://www.clinpgx.org/clinicalAnnotation/982030873 |
982030887 | rs3761555 | rs3761555 | GRIA3 | CC | 3 | Efficacy | antidepressants;Selective serotonin reuptake inhibitors;venlafaxine | Major Depressive Disorder | Patients with the CC genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment. | https://www.clinpgx.org/clinicalAnnotation/982030887 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.